Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
43 Cards in this Set
- Front
- Back
- 3rd side (hint)
What is starting dose for Amaryl?
|
1-2 mg q.d.
|
hyphenated amount
|
|
What is maintenance dose of Amaryl?
|
1-4 mg q.d.
|
hyphenated
|
|
What is maximum dose of Amaryl?
|
8 mg qd
|
|
|
What is hypoglycemic rate for Amaryl
|
0.9 to 1.7%
|
|
|
How is Amaryl excreted? (percentages)
|
Urine/kidneys - 60%
Feces - 40% |
|
|
What are the three indications of Amaryl?
|
As an adjunct to diet and exercise:
1. monotherapy 2. combo therapy with metformin (glucophage) 3. combo therapy with insulin |
|
|
Can for sulfonylureas cause weight gain?
|
Yes
|
|
|
What is the MOA of Amaryl?
|
Release of insulin from functioning pancreatic beta cells.
Increased sensitivity of peripheral tissues to insulin. Decrease in hepatic glucose production. |
|
|
What is dose for renally impaired patient on Amaryl?
|
1 mg
|
|
|
What are the available strengths of Amaryl?
|
1 mg
2 mg 4 mg (2 and 4 mg strengths are sampled) |
|
|
What is the drug class of Amaryl?
|
Sufonylurea
|
|
|
What is the generic name of Amaryl?
|
Glimiperide
|
|
|
What are the contraindications to Amaryl?
|
Known sensitivity to the drug.
Diabetic ketoacidosis. |
|
|
What is the effect of Amaryl on blood glucose?
|
2.0 percentage-point decrease in A1C vs placebo as monotherapy
28% reduction from baseline in FPG 40% reduction in 2-hour PPG |
|
|
What is effect of Amaryl on first-phase insulin secretion?
|
55%
|
|
|
Is Amaryl safe for renally impaired patients?
|
Yes, proven safety to a creatinine clearance of 9.4 mL/min.
|
|
|
What are the most common adverse reactions for Amaryl?
|
Dizziness - 1.7%
Asthenia - 1.6% Headache - 1.5% Nausea - 1.1% |
|
|
The combination of Amaryl and what sensitizer have a synergistic effect?
|
Metformin (Glucophage)
|
|
|
What are the two major defects of type 2 diabetes mellitus?
|
Insulin resistance
Impaired insulin secretion |
|
|
What is effect of Amaryl on weight and lipids?
|
Weight neutral - 6.67 pound reduction over 18 months
Lipid neutral - no deleterious changes in lipoprotein, 11.99 reduction in total cholesterol, 8.12 reduction from baseline LDL |
|
|
What is the half-life of Amaryl?
|
9 hours
|
|
|
List some key points about Amaryl.
|
1. Significant A1C reductions through FBG and PPG
2. Glucose mediated response 3. Low incidence of hypoglycemia 4. Synergistic effect in combo with metformin 5. Flexible, once-daily dosing 6. Safe in renally impaired patients |
|
|
Amaryl restores what type of insulin secretion?
|
Endogenous insulin
|
|
|
Amaryl is unique in that it is the only sulfonylurea that improves both ________ and __________ insulin response
|
First and second phase
First phase = 1-3 min Second phase = 60 min up to 2-3 hrs |
|
|
List some examples of second-generation sulfonylureas
|
Amaryl, Glyburide (Diabeta, Micronase, Glynase), Glipizide (Glucotrol, Glucotrol XL)
|
|
|
What are the two defects of type 2 diabetes?
|
insulin resistence and insulin deficiency
|
|
|
Indications of metformin
|
monotherapy as adjunct to diet and exercise (first line therapy)
combination with SU combination with insulin |
|
|
Mechanism of action of metformin
|
Biguanide class exerts glucose-lowering effect by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity
|
|
|
Does metformin have any effect on insulin secretion by the pancreatic beta cells?
|
no
|
|
|
TZD's mechanism of action is what?
|
improve sensitivity of peripheral tissues (liver, muscle and adipose tissue) to insulin, but they do not target insulin secretion
|
|
|
What are the available TZD agents?
What are the indications for TZDs |
Avandia - rosiglitazone
Actos - pioglitazone adjunct to diet and exercise, monotherapy, combo with SU, metformin, or insulin. |
|
|
What are the alpha-glucosidase inhibitors, their MOA, and indications?
|
acarbose - Precose
miglitol - Glyset MOA - delay glucose absorption in the GI tract, do not enhance insulin secretion Indicated as monotherapy, combo with SU |
|
|
What are the meglitinide analogs and MOA?
|
repaglinide and nateglinide
MOA - restore endogenous insulin secretion, but have short duration of action and must be taken with meals |
|
|
What did the Sonnenberg trial study?
|
Evaluated 3 mg bid to 6 mg qd with Amaryl for efficacy.
Proved Amaryl helps correct deficiencies in body's physiologic response to meals. Studied safety profile, with low rate of hypoglycemia |
|
|
The Riddle study (listed in PI) compared combo therapy with Amaryl and insulin (70/30) vs placebo.
What was result? |
Study showed less insulin was needed (38% less)
|
|
|
Describe the Schade study in relation to Amaryl use
|
Amaryl vs placebo (249 patients)
Studied safety, efficacy, and dosing Efficacy - reduced A1C from 9.1 to 6.7, fasting down by 46 mg/dL, and PPG down by 72 mg/dL. 69% achieved tight control Safety - safe for renally impaired, low incidence of hypo Dosing - Half life of 9 hours, convenient once daily dosing for increased compliance |
|
|
What dose of Amaryl was most common for the Schade study?
|
1 to 6 mg
|
|
|
What does metformin have a warning against in its PI?
|
Lactic acidosis - must be used in caution in patients with renal disease and monitoring of liver function should be done
|
|
|
Metformin is contraindicated for:
|
Patients with renal disease or dysfunction.
Patients with CHF Known hypersensitivity to drug Acute or chronic metabolic acidosis, diabetic ketoacidosis |
|
|
What are the primary AE's associated with metformin use?
|
Diarrhea (11.7%), nausea, vomiting, flatulence
|
|
|
What is starting and maximum dose of Glucophage XR (metformin)
|
starting - 500 mg in evening
max - 2000 mg |
|
|
How is metformin excreted?
|
Unchanged in the urine
|
|
|
What was the objective, results, conclusions of the Korytkowski trial?
|
Objective - study effect of Amaryl on insulin sensitivity and secretion in type 2 diabetics (did not prove improved sensitivity)
Conclusion - No improved sensitivity, observed improvement in first and second phase insulin secretion |
|